BusinessIrvine Biotech Eledon Reports Positive Trial Data, Receives FDA Fast Track Designation
The Company's Investigational Drug, Tegoprubart, Designed to Prevent Organ Transplant Rejection, Showed Improved Patient Outcomes in Updated Phase 2 Trial Results.
















































